Xuejing Wang
10PUBLICATIONS
126CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (10)
Sort by Publication Date:
|Aug 29, 2025
TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes STK11-Mutant Tumors to Anti-PD-1 Immunotherapy.Leanne G Ahronian, Soumyadip Sahu, Minjie Zhang
|Aug 20, 2025
Phase 1/2, open-label study of oral bacterial supplementation (EDP1503) plus pembrolizumab in participants with advanced or metastatic microsatellite-stable colorectal cancer, triple-negative breast cancer, and checkpoint inhibitor-relapsed tumors.Judy S Wang, Edward R Arrowsmith, J Thaddeus Beck
|Dec 05, 2024
First Results of Migoprotafib, a Potent and Highly Selective Src Homology-2 Domain-Containing Phosphatase 2 Inhibitor in Patients with Advanced Solid Tumors.Melissa L Johnson, Beni B Wolf, Judy S Wang
|Sep 04, 2024
Results From First-in-Human Phase I Dose-Escalation Study of a Novel Bicycle Toxin Conjugate Targeting EphA2 (BT5528) in Patients With Advanced Solid Tumors.Babar Bashir, Judy S Wang, Gerald Falchook
|Jul 26, 2023
Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors.Maria Vieito, Victor Moreno, Anna Spreafico
|Jul 24, 2023
First-in-human Study of AZD5153, A Small-molecule Inhibitor of Bromodomain Protein 4, in Patients with Relapsed/Refractory Malignant Solid Tumors and Lymphoma.Erika P Hamilton, Judy S Wang, Amit M Oza
Pageof 2
Frequent Collaborators
5 joint publications
Manish R Patel
3 joint publications
David S Hong
3 joint publications
Kathleen N Moore
3 joint publications
Susanna V Ulahannan
2 joint publications
Suzanne Jones
2 joint publications
Wenjuan Wu
2 joint publications
Gerald S Falchook
2 joint publications
Geoffrey I Shapiro
1 joint publications
Johann S de Bono
1 joint publications
Anton I Rosenbaum
